Kennondale Capital Management LLC Decreases Stake in Humana Inc. (NYSE:HUM)

Kennondale Capital Management LLC lowered its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 89.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,972 shares of the insurance provider's stock after selling 24,838 shares during the quarter. Kennondale Capital Management LLC's holdings in Humana were worth $786,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in HUM. Dodge & Cox raised its holdings in Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after purchasing an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. raised its holdings in Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock worth $3,254,899,000 after purchasing an additional 1,751,857 shares in the last quarter. Norges Bank acquired a new stake in Humana during the fourth quarter worth approximately $416,202,000. GAMMA Investing LLC raised its holdings in Humana by 40,881.1% during the first quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock worth $2,066,790,000 after purchasing an additional 779,193 shares in the last quarter. Finally, Southpoint Capital Advisors LP acquired a new stake in Humana during the fourth quarter worth approximately $190,282,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on HUM shares. Cantor Fitzgerald reissued a "neutral" rating and set a $290.00 price objective on shares of Humana in a report on Thursday, May 1st. Robert W. Baird lifted their target price on shares of Humana from $270.00 to $300.00 and gave the company a "neutral" rating in a report on Tuesday, April 15th. Wall Street Zen raised shares of Humana from a "hold" rating to a "buy" rating in a report on Sunday. Barclays set a $268.00 target price on shares of Humana and gave the company an "equal weight" rating in a report on Thursday, June 12th. Finally, Raymond James Financial raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price on the stock in a report on Thursday, May 1st. Sixteen research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $282.57.

Humana Price Performance

Shares of NYSE HUM traded down $7.64 during trading on Thursday, hitting $229.48. 901,835 shares of the company were exchanged, compared to its average volume of 1,703,061. The company has a market cap of $27.70 billion, a price-to-earnings ratio of 16.23, a PEG ratio of 1.58 and a beta of 0.44. Humana Inc. has a 1 year low of $206.87 and a 1 year high of $406.09. The firm's fifty day moving average price is $234.48 and its 200 day moving average price is $256.71. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.91 and a quick ratio of 1.91.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The business's revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm earned $7.23 EPS. On average, sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.